Summary. The effect of 2 months aminoguanidine treatment on nerve conduction abnormalities was studied in streptozotocin-diabetic rats. Treatment with aminoguanidine from the induction of diabetes mellitus prevented a 22 % decrease in sciatic motor nerve conduction velocity (p < 0.00l), and a 10% deficit in sensory saphenous conduction velocity (p < 0.01). There was a 49 % increase in resistance of sciatic nerve to hypoxic conduction failure in vitro. This was not significantly affected by aminoguanidine treatment. Sciatic nerve polyol pathway metabolites, sorbitol and fructose, were elevated 10-fold by diabetes (p < 0.001). Myo-inositol levels were 18 % decreased by diabetes. Aminoguanidine treatment had no significant effect on sorbitol, fructose or myo-inositol levels. Aminoguanidine has been identified as both an inhibitor of the formation of advanced glycation end products, and an aldose reductase inhibitor. The data suggest that beneficial actions on nerve function do not depend on the latter property. They support the notion that advanced glycation end products contribute to the aetiology of early diabetic neuropathy, possibly acting via a vascular mechanism, and that aminoguanidine treatment may have therapeutic applications.
Several hypotheses have been proposed to account for the abnormalities in nerve function found in diabetes. One view highlights the importance of metabolic changes in neurons and Schwann cells. Thus, a hyperglycaemia-induced increase in polyol pathway flux may lead to reduced nerve myo-inositol levels and phosphoinositide turnover, compromising Na § -K+-ATPase activity. The consequent changes in ionic homeostasis could be responsible for functional deficits such as reduced conduction velocity, increased resistance to ischaemic conduction failure (RICF), and long-term morphological deficits including axonopathy [1] . Aldose reductase inhibitors (ARI) correct nerve dysfunction in diabetic rats [2] [3] [4] , and can produce improvements in fibre regeneration in patients [5] .
Low and co-workers [6] have emphasized the importance of vascular factors by demonstrating that rat sciatic nerves have reduced endoneurial blood flow and are hypoxic to an extent sufficient to cause dysfunction. Blood flow may be improved and function is normalized by vasodilator treatment [7] [8] [9] . Endoneurial hypoxia has also been measured in neuropathic patients [10] . Several reports of non-diabetic rats reared under hypoxic conditions, and of non-diabetic patients with chronic obstructive airway disease, have stressed the similarities of nerve function with those found in diabetes [11] [12] [13] . There are a number of possible causes of impaired nerve perfusion, including increased vascular reactivity [14, 15] , deficits in vascular endothelium production of vasodilator prostacyclin [16] and nitric oxide [17, 18] , increased synthesis of vasoconstrictor prostanoids [19] , elevated blood viscosity [20] and microvascular atherogenesis dependent on advanced glycation end products (AGE) [21] .
Aminoguanidine treatment prevents AGE formation [21] , and has recently been shown to normalize rat sciatic nerve blood flow and improve electrophysiological and morphological indices [22, 23] . However, a further report suggests that aminoguanidine possesses substantial ARI activity [24] , because there was a 75 % reduction in diabetic rat lens sorbitol levels when treated for 98 days with a dose of 25 mg/kg body weight which was very similar to that used in studies of nerve function (25 or 50 mg/kg) [22] . Given that ARIs correct nerve function and morphology [2] [3] [4] , and may improve blood flow [25] , it is not clear whether the beneficial effects of aminoguanidine depend on AGE as opposed to polyol pathway inhibition. The aim of this investigation was to measure the effect of aminoguanidine on nerve polyol pathway metabolites for correlation with any conduction velocity improvements. A second aim was to investigate aminoguanidine effects on RICF as this has not previously been examined.
Materials and methods
Male Sprague-Dawley rats (Aberdeen University breeding colony), 19 weeks of age at the start of the study were used. One group of nondiabetic animals acted as onset controls. Others were given streptozotocin (40 mg/kg in 20 mmol/l sodium citrate buffer, pH 4.5, i.p.). Diabetes was verified 24h later by estimating hyperglycaemia and glycosuria (Visidex II and Diastix; Ames, Slough, Bucks., UK). Samples for plasma glucose measurement were taken the day of final experiments. Diabetic animals were divided into two groups, one of which was untreated for 2 months. The other group was treated with aminoguanidine (Sigma, Poole, Dorset, UK) 7.35 retool/1 given in the drinking water, which did not affect the approximately 250 mt of water per day consumed by the diabetic rats. This treatment regimen has previously been demonstrated to prevent kidney mesangial expansion with diabetes, and results in plasma aminoguanidine levels similar to those commonly obtained using a daily i.p. injection [26] .
In final experiments (1-1.5 g/kg urethane anaesthesia i. p.), conduction velocity was measured in vivo between the sciatic notch and knee for motor branches supplying tibialis anterior (peroneal division) and gastrocnemius (tibial division) muscles. Sensory conduction velocity was measured in the saphenous nerve between groin and ankle, the methods for which have previously been described in detail [27] .
RICF was measured in vitro as previously described [27] . The contralateral sciatic trunk was removed and mounted on bipolar stimulating (proximal end) and recording (distal end) electrodes in a chamber at 35 ~ It contained Krebs-Ringer solution with 5.5 retool/1 glucose for nerves from non-diabetic rats, and 40 mmol/1 glucose for the diabetic groups. Bathing fluid was gassed with a mixture of 95 % 0 2 : 5 % CO2. Nerves were equilibrated for 30 rain, then the chamber was refilled with mineral oil pre-gassed with 100 % N2 for i h. Nerves were stimulated with just supramaximal pulses (1 Hz, 0.05 ms width, 10 mA) and compound action potential amplitude was monitored at 2-min intervals until it fell below 10 % of its initial value.
Sciatic nerve sugars and polyols were determined by gas chromatography of trimethyl-silyl derivatives prepared from aqueous deproteinized extracts [28] .
Statistical analysis
Data are expressed as means + SEM.One-way analysis of variance was performed, followed by the Bonferroni-corrected t-test to assign differences to individual between-group comparisons when overall significance (p < 0.05) was attained, using commercial software (Instat, GraphPad, San Diego, Calif., USA). Table 1 shows plasma glucose levels and body weights for all groups. Plasma glucose was elevated five-fold by diabetes, and there was a 22 % weight loss. Aminoguanidine 947 treatment did not have a significant effect on these parameters.
Results
Data for motor nerve conduction velocity are shown in Figure i for gastrocnemius and tibialis anterior sciatic motor branches. Conduction velocity was 20 % and 23 % reduced by untreated diabetes, respectively (p < 0.001, both nerves). Aminoguanidine treatment prevented this reduction in conduction velocity (p < 0.001, both nerves), values were not significantly different from controls. Sensory saphenous conduction velocity is also shown in Figure 1 , there was a 10 % decrease with diabetes (p < 0.05), which was prevented by treatment (p < 0.01). Figure 2 shows data for RICF, and the decline in compound action potential amplitude with increasing duration of hypoxia. The decline was prolonged in nerves from untreated diabetic rats compared to controls (p < 0.05 from 18 min onward); a similar effect was seen for aminoguanidine treatment (p < 0.01 from 22 rain onward). There were no significant differences between diabetic and aminoguanidine-treated groups at any time point. The inset graph of Figure 2 shows the times taken for an 80 % decrease in compound action potential amplitude (Ts0). These were 49 % elevated by diabetes (p < 0.001), and 37 % increased (p < 0.01) in the aminoguanidine-treated group compared to controls. There was no significant effect of aminoguanidine compared to untreated diabetes on Ts0. Figure 3 shows sciatic nerve sorbitol, fructose and myoinositol levels. Sorbitol and fructose were 12-fold and 9-fold elevated by diabetes respectively (bothp < 0.001) and this was completely unaffected by aminoguanidine treatment. Myo-inositol was 16% reduced in the diabetic group compared to controls, although this did not reach statistical significance. In the aminoguanidine-treated diabetic group, a similar 20 % decrease in myo-inositol was statistically significant (p < 0.05) compared to nondiabetic but not to diabetic controls. 
Discussion
The data demonstrate that aminoguanidine treatment prevents the development of motor and sensory conduction velocity deficits associated with diabetes. This occurred in the absence of any effect on elevated sciatic nerve N. E. Cameron et al.: Aminoguanidine effects on nerve polyol pathway metabolites, or on myo-inositol levels. Thus, there is no evidence from these experiments that the beneficial effects of aminoguanidine depended on an ARI action. The results also suggest that correction of a putative mechanism of nerve dysfunction, based on polyol pathway activity and a phosphoinositide-turnover-dependent reduction in Na + -K + -ATPase activity [11, is not relevant to the effects of aminoguanidine. This is in accord with previous findings for chronic vasodilator treatments [8, 9] . The lack of effect of aminoguanidine on nerve sorbitol concentration contrasts with data presented by Kumari and co-workers [24] who suggested that aminoguanidine slows the development of cataracts in diabetic rats in vivo by inhibiting polyol pathway activity. This group also provided an in vitro demonstration that aminoguanidine inhibits aldose reductase, although the Ki value reported was at least two orders of magnitude greater than the dose used for the in vivo study. Thus, other interpretations of the effect of aminoguanidine on lens cataracts in vivo are possible and may be more appropriate. Aminoguanidine could have a primary effect on cataracts by preventing the formation of AGE, whereas the apparent sorbitol-lowering properties may have resulted indirectly from other mechanisms, for example by an increase in lens sorbitol permeability. Whatever the reason for the difference between this study and that of Kumari et al. [24] , it is clear that aminoguanidine cannot be considered an effective ARI at the doses commonly used [22, 23, 26] to prevent the accumulation of AGE. The potential effect of aminoguanidine on lens sorbitol concentration also requires further confirmatory studies to establish the mechanisms responsible.
The conduction velocity data support a previous report of a longer-term study [22] , where aminoguanidine treatment prevented a progressive decline in sciatic-tibial nerve conduction velocity over a 24-week period. However, for caudal nerve in that study, results were more complex. Aminoguanidine caused delayed normalization of an initial defect, which developed during the first 8 weeks of diabetes of the treatment period. The reason for the difference between sciatic and caudal nerves is unclear.
The action of aminoguanidine may depend on prevention of AGE-related vascular changes. Low and co-workers [22] demonstrated that aminoguanidine prevented a decrease in sciatic resting endoneurial blood flow for over 16 weeks of diabetes. Vasodilator treatments cause similar changes in blood flow and nerve function [7] [8] [9] , thus, the vascular effect of aminoguanidine should be sufficient to account for its action on conduction velocity. Aminoguanidine is not a generalvasodilator, and had no effect on nerve blood flow in non-diabetic rats [22] . There are, however, several potential AGE effects on microvasculature in diabetes. In the long term, aminoguanidine prevents glomerular basement membrane thickening [21] . AGEs have been implicated in atherogenesis because they stimulate macrophage recognition and uptake, which could lead to smooth muscle proliferation in response to macrophage-derived growth factor [29] . Aminoguanidine also prevents increases in vascular permeability in retina and nerve, perhaps indicating preservation of endothelial in-tegrity [30] ; however, diabetic effects on the blood-nerve barrier have been disputed [22] . AGEs may have a direct effect on vascular endothelium-derived relaxing factor as they quench nitric oxide in vitro [31] . Depressor responses to acetylcholine are reduced in diabetic rats and patients [31, 32] . Endothelium-dependent relaxation to acetylcholine is impaired in aortas and several vascular beds in streptozotocin and spontaneously diabetic rats [17, 18, [33] [34] [35] [36] [37] [38] , and in vascular tissue from diabetic patients [39] studied in vitro. Aminoguanidine treatment prevented the development of impaired depressor responses to acetylcholine for over 2 months in streptozotocin-diabetic rats [31] . Thus, the forestalment of abnormal endotheliumdependent nitric oxide vasodilator action on vascular smooth muscle could make a major contribution to normalizing nerve blood flow and conduction velocity.
Aminoguanidine treatment did not have a significant effect on sciatic nerve RICE As for conduction velocity, the mechanisms underlying RICF have been disputed. The metabolic hypothesis suggests that it is a polyol-pathway related consequence of reduced Na § § activity, hence diminished demand for ATP and oxygen [1] . The vascular hypothesis attributes RICF to an adaptation towards increased reliance on anaerobic metabolism as a result of chronic endoneurial hypoxia [40] . In isolation, the data might be taken to support the metabolic hypothesis; sorbitol and fructose, the indicators of polyol pathway activity, were not reduced by aminoguanidine treatment, and RICF was unchanged. ARIs can prevent the development of RICE [4, 41] , although this has been disputed [42] . However, results from vasodilator treatment experiments also show that RICF can be prevented without any effect on nerve polyol levels [8, 9] . We have found RICF to be a much more sensitive indicator of diabetic nerve dysfunction than conduction velocity, and correspondingly more difficult to correct. For vasodilator treatments, this may depend on relative efficacy. Over 2 months of streptozotocin-diabetes increased RICF was completely prevented by the angiotensin converting enzyme inhibitor lisinopril (20 mg/kg) [9] , partially prevented by the (x~-adrenoceptor blocker prazosin (5 mg/kg) [8] , and unaffected by the calcium channel antagonist nifedipine (40 mg/kg) (S. Robertson, N.E. Cameron, M.A. Cotter, unpublished observations); despite this, all treatments completely and indistinguishably prevented motor and sensory conduction velocity deficits. Thus, it is plausible that a vascular effect of aminoguanidine in this investigation was simply not powerful enough to prevent the development of RICE. This notion is indirectly supported by the study by Low and co-workers [22] , where caudal nerve electrophysiology showed early evidence of dysfunction despite treatment. In addition, although resting sciatic blood flow was normalized by aminoguanidine in that study, an increase in conjugated dienes was nevertheless present, indicating that nerves remained under some oxidative stress. This could relate to impaired flow increases when nerves were active, which could be a stimulus for RICF development.
In conclusion, aminoguanidine prevented the development of conduction velocity deficits in diabetic rats, by a mechanism that did not depend on inhibition of polyol pathway activity. AGE-dependent effects, probably vascular related, may contribute to the aetiology of early experimental diabetic neuropathy, and this could have therapeutic implications.
